These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11728242)

  • 21. Deep venous thrombosis in children and adolescents.
    Levy ML; Granville RC; Hart D; Meltzer H
    J Neurosurg; 2004 Aug; 101(1 Suppl):32-7. PubMed ID: 16206969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thromboprophylaxis and early antithrombotic therapy in patients with acute ischemic stroke and cerebral venous and sinus thrombosis.
    Busch M; Masuhr F
    Eur J Med Res; 2004 Apr; 9(4):199-206. PubMed ID: 15210400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the risks and benefits of differing prophylaxis regimens for the treatment of deep venous thrombosis and pulmonary embolism in neurosurgery.
    Epstein NE
    Surg Neurol; 2005 Oct; 64(4):295-301; discussion 302. PubMed ID: 16181995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endovascular management of acute deep vein thrombosis.
    Blum A; Roche E
    Am J Med; 2005 Aug; 118 Suppl 8A():31S-36S. PubMed ID: 16125512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hirudin for prophylaxis and treatment of deep vein thrombosis.
    Kemkes-Matthes B
    Semin Thromb Hemost; 2002 Oct; 28(5):455-8. PubMed ID: 12420241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing Raynaud's phenomenon: a practical approach.
    Adee AC
    Am Fam Physician; 1993 Mar; 47(4):823-9. PubMed ID: 8438681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update in the treatment of venous thromboembolism.
    Garcia DA; Spyropoulos AC
    Semin Respir Crit Care Med; 2008 Feb; 29(1):40-6. PubMed ID: 18302085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of deep vein thrombosis with continuous intravenous infusion of LMWH in children--an alternative to subcutaneous application when needed.
    Blatný J; Fiamoli V
    Vnitr Lek; 2009 Mar; 55(3):227-32. PubMed ID: 19378852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial treatment of venous thromboembolism.
    McRae SJ; Ginsberg JS
    Circulation; 2004 Aug; 110(9 Suppl 1):I3-9. PubMed ID: 15339875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective.
    de Lissovoy G
    Am J Manag Care; 2001 Nov; 7(17 Suppl):S535-8; discussion S538-44. PubMed ID: 11732664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current medical and surgical management of Raynaud's syndrome.
    Landry GJ
    J Vasc Surg; 2013 Jun; 57(6):1710-6. PubMed ID: 23618525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low molecular weight heparin for deep vein thrombosis in glioma patients.
    Schmidt F; Faul C; Dichgans J; Weller M
    J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possibilities for clinical use of prostacyclin in vascular disease.
    Poredos P
    Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.
    Mazokopakis EE; Vrentzos GE; Ganotakis ES
    Curr Med Res Opin; 2003; 19(6):565-6. PubMed ID: 14594529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase inhibitors in Raynaud's phenomenon.
    Levien TL
    Ann Pharmacother; 2006; 40(7-8):1388-93. PubMed ID: 16835313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raynaud's phenomenon in mixed connective tissue disease.
    Grader-Beck T; Wigley FM
    Rheum Dis Clin North Am; 2005 Aug; 31(3):465-81, vi. PubMed ID: 16084319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.